Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLT212
- Development stage
- Preclinical
- Lead developer
- Pilatus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PLT212 (also known as PLT-212) is an early-stage investigational immuno-oncology therapeutic candidate being developed by Pilatus Biosciences. It is a monoclonal antibody designed to target an undisclosed metabolic checkpoint within the tumor microenvironment to reprogram the immune system and address hard-to-treat cancers. Currently in the discovery and preclinical stage of development, PLT212 is part of Pilatus Biosciences' pipeline of first-in-class therapies aimed at tackling the immune and metabolic challenges underlying neoplasms.
- Other names
- PLT 212PLT212PLT-212
Beyond the preview
Go deeper on PLT212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLT212.